|Dr. Brett P. Monia Ph.D.||Founder, CEO & Director||1.34M||2.3M||1961|
|Ms. Elizabeth L. Hougen||Exec. VP & CFO||862.13k||2.26M||1962|
|Mr. Patrick R. O'Neil Esq.||Exec. VP, Chief Legal Officer & Gen. Counsel||822.93k||N/A||1974|
|Dr. Stanley T. Crooke||Scientific Advisor||1.31M||327.85k||1945|
|Ms. B. Lynne Parshall||Sr. Strategic Advisor & Director||1.03M||376.15k||1954|
|Dr. Richard S. Geary||Exec. VP & Chief Devel. Officer||868.91k||1.25M||1958|
|Mr. Joel Edwards||VP of Corp. Operations||N/A||N/A||1961|
|Mr. Darren Gonzales||Chief Accounting Officer & Sr. VP||N/A||N/A||N/A|
|Dr. C. Frank Bennett||Exec. VP & Chief Scientific Officer||N/A||N/A||1957|
|Mr. David Nakasone||Investor Relations Officer||N/A||N/A||N/A|
Ionis Pharmaceuticals, Inc. discovers and develops RNA-targeted therapeutics in the United States. The company offers SPINRAZA for spinal muscular atrophy (SMA) in pediatric and adult patients; TEGSEDI, an injection for the treatment of polyneuropathy of hereditary transthyretin-mediated amyloidosis in adults; and WAYLIVRA, a treatment for familial chylomicronemia syndrome and familial partial lipodystrophy. It is involved in developing neurology products that include Tominersen for Huntington's diseases; Tofersen for amyotrophic lateral sclerosis (ALS); IONIS-MAPTRx for Alzheimer's diseases; IONIS-C9Rx for genetic form of ALS; ION859 for Parkinson's disease; ION464 for multiple system atrophy and Parkinson's disease; ION541 for amyotrophic lateral sclerosis; and IONIS-DNM2-2.5Rx for centronuclear myopathy. The company is also developing products for cardiometabolic disease, such as IONIS-TTR-LRx for transthyretin amyloidosis and IONIS-GHR-LRx for acromegaly; IONIS-APOCIII-LRx for familial chylomicronemia syndrome and TG- driven diseases; IONIS-APOCIII-LRx for treatment resistant hypertension; Pelacarsen for Lp(a)cardiovascular disease risk reduction; Vupanorsen for sHTG/CVDRR; IONIS-FXI-LRx for clotting disorders; ION449 for cardiovascular diseases; and IONIS-GCGRRx for diabetics. In addition, it develops IONIS-ENAC-2.5Rx for cystic fibrosis and chronic obstructive pulmonary disease; IONIS-PKK-LRx for hereditary angioedema; Danvatirsen for cancer; IONIS-TMPRSS6-LRx for beta-thalassemia and iron toxicity; IONIS-HBVRx for hepatitis B virus; IONIS-AR-2.5Rx for prostate cancer; IONIS-FB-LRx for age-related macular degeneration and IgA nephropathy; and ION357 for retinitis pigmentosa. It has a collaboration agreement with AstraZeneca; GlaxoSmithKline plc; Janssen Biotech, Inc.; Bayer AG; Novartis AG; Pfizer, Inc.; Biogen Inc.; Flamingo Therapeutics, Inc.; and Roche. Ionis Pharmaceuticals, Inc. was founded in 1989 and is based in Carlsbad, California.
Ionis Pharmaceuticals, Inc.’s ISS Governance QualityScore as of September 26, 2021 is 6. The pillar scores are Audit: 4; Board: 8; Shareholder Rights: 6; Compensation: 3.